ESLA net incomeQ2 2026-$2.31M
ESLA net income was -$2.31M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.54M a year earlier. For the full fiscal 2025 it was -$13.06M.
Estrella Immunopharma Inc. (ESLA) financials
For the twelve months ended Jun 30, 2026, Estrella Immunopharma Inc. reported -$10.01M of net income.
- Net income, TTM
- -$10.01M
- EPS, diluted, TTM
- -$0.24
- Cash
- $100.0K
- Market cap
- $22.1M
FY2021FY2025
ESLA revenue and earnings growth
ESLA EPSQ2 2026-$0.05
ESLA diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.15 a year earlier. For the full fiscal 2025 it was -$0.35.
Income statement
| Line item | Dec 31, 2025 | Jun 30, 2024 | Jun 30, 2023 | Dec 31, 2021 |
|---|---|---|---|---|
| Research and development | $10.25M | $4.11M | $10.45M | - |
| Selling, general and admin | $2.81M | $3.20M | $663.2K | - |
| Operating income | -$13.06M | -$7.31M | -$11.11M | -$249.1K |
| Pre-tax income | -$13.06M | -$7.31M | -$11.11M | -$247.7K |
| Income tax | $838 | $1.6K | - | $0 |
| Net income | -$13.06M | -$7.31M | -$11.11M | -$247.7K |
| EPS, basic | -$0.35 | -$0.27 | -$36.35 | -$1.52 |
| EPS, diluted | -$0.35 | -$0.27 | -$36.35 | -$1.52 |
| Diluted shares | 36.8M | 27.1M | 305,748 | 1.2M |
Balance sheet
| Line item | Dec 31, 2025 | Jun 30, 2024 | Jun 30, 2023 | Dec 31, 2021 |
|---|---|---|---|---|
| Cash and equivalents | $1.38M | $4.17M | $2.48M | $478.9K |
| Receivables | - | - | $273.1K | - |
| Current assets | $1.68M | $4.45M | $2.75M | $616.0K |
| Total assets | $3.18M | $4.45M | $3.03M | $45.80M |
| Current liabilities | $13.54M | $180.7K | $9.76M | $73.2K |
| Total liabilities | $13.54M | $180.7K | $9.77M | $1.62M |
| Shareholders' equity | -$10.37M | $4.27M | -$11.74M | -$1.01M |
Cash flow
| Line item | Dec 31, 2025 | Jun 30, 2024 | Jun 30, 2023 | Dec 31, 2021 |
|---|---|---|---|---|
| Operating cash flow | -$1.79M | -$16.07M | -$1.34M | -$316.2K |
| Investing cash flow | - | $4.96M | -$273.1K | -$45.19M |
| Financing cash flow | $2.25M | $12.79M | - | $45.98M |
| Stock-based compensation | $619.0K | $1.19M | $409.6K | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.40M | $1.40M | $25.4K | $4.15M | $4.66M | $1.41M | $3.52M | $25.0K | $75.5K | $483.5K | $2.58M | $2.62M |
| Selling, general and admin | $684.0K | $891.8K | $587.8K | $648.5K | $883.7K | $694.1K | $424.4K | $444.5K | $945.2K | $1.39M | $155.7K | $117.7K |
| Operating income | -$2.08M | -$2.29M | -$613.2K | -$4.80M | -$5.54M | -$2.10M | -$3.95M | -$469.5K | -$1.02M | -$1.87M | -$169.2K | -$2.74M |
| Pre-tax income | -$2.31M | -$2.29M | -$613.2K | -$4.80M | -$5.54M | -$2.10M | -$3.95M | -$469.5K | - | -$1.87M | -$54.9K | -$43.9K |
| Income tax | - | - | -$25 | $0 | $850 | $13 | $1.6K | - | - | - | $21.1K | $19.5K |
| Net income | -$2.31M | -$2.29M | -$613.2K | -$4.80M | -$5.54M | -$2.10M | -$3.95M | -$469.5K | -$1.02M | -$1.87M | -$76.0K | -$2.74M |
| EPS, basic | -$0.05 | -$0.05 | -$0.01 | -$0.13 | -$0.15 | -$0.06 | -$0.11 | -$0.01 | -$0.03 | -$1.78 | - | -$8.13 |
| EPS, diluted | -$0.05 | -$0.05 | -$0.01 | -$0.13 | -$0.15 | -$0.06 | -$0.11 | -$0.01 | -$0.03 | -$1.78 | - | -$8.13 |
| Diluted shares | 43.0M | 42.1M | - | 37.1M | 36.2M | 36.2M | 36.4M | 35.5M | 35.2M | 1.1M | - | 337,275 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $100.0K | $1.93M | $1.38M | $1.63M | $1.32M | $421.5K | $4.17M | $4.73M | $9.05M | $22.14M | $2.48M | $2.66M |
| Receivables | - | - | - | - | - | - | - | - | - | - | $273.1K | - |
| Current assets | $1.82M | $2.16M | $1.68M | $2.02M | $1.48M | $944.3K | $4.45M | $8.63M | $9.45M | - | $2.75M | $81.9K |
| Total assets | $1.82M | $3.66M | $3.18M | $3.52M | $2.98M | $2.44M | $4.45M | $8.63M | $9.45M | $27.35M | $3.03M | $9.78M |
| Current liabilities | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $180.7K | $138.5K | $398.7K | $17.28M | $9.76M | $1.22M |
| Total liabilities | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $180.7K | $138.5K | $398.7K | $17.28M | $9.77M | $2.77M |
| Shareholders' equity | -$7.43M | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | $4.27M | $8.49M | $9.05M | $10.07M | -$11.74M | -$9.11M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.78M | -$6.70M | -$177.5K | -$727.3K | -$414.9K | -$466.0K | -$291.5K | -$4.23M | -$11.27M | -$275.2K | -$43.2K | -$275.7K |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | $5.07M | -$112.3K | -$136.5K | $77.8K |
| Financing cash flow | $4 | $7.24M | -$64.8K | $1.04M | $1.31M | -$29.5K | -$270.3K | -$84.1K | -$6.90M | $20.05M | - | $186.5K |
| Stock-based compensation | $145.3K | $146.7K | $148.4K | $152.4K | $159.1K | $159.1K | $0 | $0 | $0 | $1.19M | $102.4K | $102.4K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.20 | 0.24 | 0.12 | 0.15 | 0.16 | 0.22 | 24.65 | 62.34 | 23.69 | - | 0.28 | 0.07 |
Source: XBRL data Estrella Immunopharma Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ESLA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ESLA | - | - | -$10.01M | - | $22.1M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.89B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $208.48B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $90.38B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.58B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.46B |
| RVMD | $0 | - | -$1.13B | - | $37.27B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.50B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $16.94B |
ESLA FAQ
5 questionsIs ESLA profitable?
No. Estrella Immunopharma Inc. reported a net loss of $10.01M for the twelve months ended Jun 30, 2026.How much cash and debt does ESLA have?
Estrella Immunopharma Inc. reported $100.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ESLA earnings per share?
Diluted earnings per share were -$0.24 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ESLA last report financial results?
The latest statements here come from Estrella Immunopharma Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this ESLA financial data come from?
Quantisnow builds these statements from the structured XBRL data Estrella Immunopharma Inc. files with the SEC. It is provided for information only and is not investment advice.